Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ViRexx Medical has completed enrolment and treatment in a phase I trial for HepaVaxx B Vaccine, the lead candidate from the company's novel Chimigen vaccine platform.
Subscribe to our email newsletter
HepaVaxx B Vaccine consists of a recombinant chimeric molecule containing a hepatitis B viral antigen and a portion of a murine monoclonal antibody. The molecule is designed to target dendritic cells, which play a significant role in antigen presentation and initiation of an immune response.
The trial has enrolled and vaccinated its target of 15 healthy volunteers with a subcutaneous injection of HepaVaxx B Vaccine. There were no significant adverse events associated with the treatment.
In preclinical testing, HepaVaxx B Vaccine has produced both cellular and humoral immune responses. ViRexx believes that the development of humoral and cellular responses may be effective in clearing the virus from patients with chronic hepatitis B infection.
“Establishing a strong safety profile for this novel therapeutic vaccine is critical to the advancement of our Chimigen platform,” said Dr Lorne Tyrrell, CEO and chief scientific officer of ViRexx. “Existing hepatitis B antiviral therapies are effective in only approximately 20% to 30% of chronic carriers. The therapeutic potential of HepaVaxx B Vaccine, used alone or in combination with existing anti-viral therapies could have an enormous impact for these chronic carriers.”